ClinicalTrials.gg
Active, not recruitingNCT03653273STOP-I-SEPUpdated Mar 30, 2026

Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)

A Phase 3 interventional study of DMT withdrawal and DMT continuation in Multiple Sclerosis, sponsored by Rennes University Hospital. Active, not recruiting at 27 sites in France. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Rennes University Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Multiple Sclerosis by Rennes University Hospital — 2 open to participants now, 3 under way, 2 of them phase 3. Multiple Sclerosis · Rennes University Hospital.

Planned enrollment
2nd of 11
250 · median 124
Started
2019
with 3 others
Phase 3
4 of 20
1 open now
Registered
10th of 20
by date

Among the 20 studies in Multiple Sclerosis by Rennes University Hospital, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2019, is one of 4 in phase 3, and was the 10th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 20 studies in Multiple Sclerosis by Rennes University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Multiple Sclerosis by Rennes University Hospital, or all of them as a file.
02

Study summary

Further controlled and randomized prospective studies in Multiple sclerosis, analyzing the potential impact of treatment discontinuation on disability progression, focal disease activity and quality of life are needed. The optimum patient age and duration of inactive SPMS before treatment withdrawal and the monitoring procedures also need to be specified, the ultimate goal being to provide evidence-based recommendations for clinical practice. Following the previous retrospective experience, we decided to drive a multicenter prospective study in France based on the hypothesis that stopping disease modifying therapy will not induce an increased risk of disability progression and relapse in selected SPMS patients (older patients without lesion activity) but will improve the quality of life and may reduce treatment-related costs.

Read the detailed description

Multiple sclerosis (MS) usually evolves over decades and can present several phenotypes. Approximately 85% of newly diagnosed Multiple Sclerosis (MS) patients present the Relapsing-Remitting MS (RRMS) phenotype. After a mean time of approximatively 20 years, a large majority of these patients evolve to the so-called "Secondary Progressive MS" (SPMS) phase. SPMS is characterized by an irreversible disability progression not related to relapses, although relapses could be superimposed. Nevertheless, the shift in-between RRMS and SPMS is not clear. Different subtypes of SPMS have been recently defined by F Lublin et al. This classification takes into account persistent focal inflammatory activity (active vs inactive SPMS) along with disease progression (progressing vs non-progressing SPMS). In clinical routine, it is important to identify these stages of MS as they differently respond to the disease modifying therapies (DMTs).

Introducing DMTs during the RRMS phase had consistently demonstrated a significant impact on the annual relapse rate (ARR) and on the short-term disability progression. Conversely, during the SPMS phase, the impact of DMTs remained uncertain on disability progression, especially in older patients, with "inactive" disease. As a matter of fact, the DMTs are considered to be anti-inflammatory by nature, but the focal inflammation reduces with age and disease duration.

In addition, the DMTs have side effects and cost approximately 10,000 euros per year and per patient. In this context, the usefulness of continuing DMTs in "inactive" SPMS patients older than 50 years is questionable.

In a preliminary retrospective study conducted at our Institute which enrolled 100 SPMS patients, the ARR remained stable 3 years after treatment withdrawal (0.07, 95% CI [0.05, 0.11]), relative to the 3 years prior to treatment withdrawal (0.12, [0.09, 0.16]). EDSS scores were available for 94 patients The percentage of patients experiencing a significant increase of their EDSS score during the 3 years after treatment withdrawal also remained stable compared to the 3 years prior treatment withdrawal. These preliminary data support the safety of DMTs withdrawal in selected SPMS patients. However, further prospective studies are needed to provide evidence-based guidelines for daily practice.

This randomized controlled clinical trial thus aims to compare SPMS patients older than 50 years without evidence of focal inflammatory activity for 3 years, stopping DMTs versus patients with the same criteria still receiving treatment. We hypothesize that stopping DMTs will not induce an increased risk of disability progression or relapse in SPMS patients but will improve their quality of life and have an impact on treatment-related costs.

So far, the impact of DMTs withdrawal in a selected SPMS population has not been explored. Having evidence-based recommendations on the treatment management of these patients is essential, considering the consequences in terms of disability, relapses, side effects, quality of life and costs. DMTs in MS are now available since 20 years, with an increasing number of approved molecules. As a matter of fact, this question concerns a large number of patients: a retrospective analysis of patients included in the Rennes EDMUS database allowed to identify 71 SPMS patients older than 50 years and without evidence of focal inflammatory activity for 3 years actually undergoing a DMT.

For evident conflict of interests, the pharmaceutical firms will not promote or fund clinical trials on treatment withdrawal. A randomized controlled study initiated by academia and financed by public funding should be performed to explore these questions. We will evaluate the impact of these changes from the patient and the health system's points of view. The results of this clinical trial will lead to a concrete change in clinical practice.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • multiple sclerosis
  • secondary progressive
  • disease modifying treatment
  • medico economic impact
  • treatment withdrawal
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients > 50 years old;
  • Secondary progressive phenotype for at least 3 years; The secondary progressive phenotype will be defined as progressive deterioration of disability not due to relapse, with an increase of at least 1 EDSS point since the beginning of the progressive phase (or 0.5 EDSS point if EDSS score ≥ 5.5).
  • Disease modifying therapy of MS for at least 3 years (interferon, glatiramer acetate, teriflunomide, dimethyl fumarate, cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil, rituximab, ocrelizumab); Both patients with the same DMT or with successive DMTs during 3 years can be included. It is important to note that patients could have been treated with fingolimod or natalizumab 2 or 3 years before inclusion, but not during the year before inclusion ;
  • No evidence of focal inflammatory activity for at least 3 years (no clinical relapse and no gadolinium enhancement on an MRI scan);
  • EDSS≥3.

Concomitant medications with Fampridine are allowed throughout the study, provided they have been introduced at least 1 months before inclusion.

Natalizumab and fingolimod during the year before inclusion were excluded because of the risk of recurrence of inflammatory activity or even rebound of inflammatory activity after withdrawal.

Both patients with the same DMT or with successive DMTs during 3 years can be included, as for example, cyclophosphamide is used for 1 or 2 years, sometimes followed by mycophenolate mofetil.

For Rituximab and Ocrelizumab, inclusion in STOP-I-SEP will be at 6 months from the last infusion to take into account the mode of action of these treatments and their specific administration scheme.

Exclusion criteria

Exclusion Criteria:

  • Patients treated with mitoxantrone or alemtuzumab, during the previous 3 years before inclusion;
  • Patients treated with natalizumab or fingolimod during the year before inclusion;
  • Change of disease modifying therapy of MS for less than a year
  • Other neurological or systemic disease ;
  • Incapacity to understand or sign the consent form ;
  • to MRI ;
  • Pregnancy or breast-feeding ;
  • Patient in another clinical trial
  • Persons referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the Public Health Code (eg minors, protected adults, …).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    DMT withdrawal

    DMT will be immediately stopped after randomization.These patients will be followed for 2 years.

    Other: DMT withdrawal

  • Active comparator
    DMT continuation

    The previously established therapy will be continued at the same dose during two years.

    Drug: DMT continuation

Interventions

  • OtherDMT withdrawal

    Group 1 (DMT withdrawal) will not undergo any disease modifying treatments (DMT).

  • DrugDMT continuation

    Group 2 (DMT continuation) may undergo the DMT . The therapy continued in this research is the one previously established, at the same dose, not implying additional precautions for use.

06

What researchers measure

Primary outcomes

  1. Disability progression measured by EDSS

    Disability progression measured by the Percentage of patients experiencing disability progression (confirmed at 6 months) at 2 years. Disability progression will be defined as an increase in the EDSS of at least 1 point if the baseline EDSS was 5.5 or less, or 0.5 point if the Baseline EDSS was more than 5.5.

    Time frame: 24 months

Secondary outcomes

  1. Time of Disability progression

    Disability progression measured by Time from DMT withdrawal to disability progression

    Time frame: 24 months

  2. Disability progression measured by composite score

    Disability progression measured by Change in a composite disability progression score (increase in the EDSS score, or an increase in the time to perform the timed 25-foot walk ≥ 20%, or an increase in the time to complete the 9-hole peg test ≥ 20%) confirmed at 6 months

    Time frame: 24 months

  3. Disability progression measured by SDMT

    Disability progression measured by Change in the SDMT score from baseline to 2-year

    Time frame: 24 months

  4. Percentage of patients with Relapse

    Relapses measured by Percentage of patients with at least one relapse from baseline to 2-year

    Time frame: 24 months

  5. Annualized relapse rate

    Relapses measured by Annualized relapse rate during 2-year

    Time frame: 24 months

  6. Time of Relapses

    Relapses measured byTime from DMT withdrawal to first relapse;

    Time frame: 24 months

  7. Percentage of patients with brain lesion

    Percentage of patients with one or more new or enlarging brain MRI (Magnetic Resonance Imaging) lesions from baseline to 2-year

    Time frame: 24 months

  8. Percentage of patients with gadolinium enhancing lesion

    Percentage of patients with at least one gadolinium enhancing lesion(s) at 6 months, and/or 1 year,and/or 2-year

    Time frame: 24 months

  9. Change in brain volume

    Change in brain volume from baseline to 2-year measured on MRI

    Time frame: 24 months

  10. Percentage of patients with no evidence of disease activity

    Percentage of patients with no evidence of disease activity (NEDA 3: no clinical relapse, no MRI activity, no disability progression) at 2-year

    Time frame: 24 months

  11. Percentage of patients who resume DMT in the treatment withdrawal group

    Percentage of patients who resume DMT in the treatment withdrawal group at 2-year

    Time frame: 24 months

  12. Quality of life measured by SEP-59 score

    Change in the SEP-59 score from baseline to 2-year;

    Time frame: 24 months

  13. Quality of life measured by EQ-5D score

    Change in the EuroQOL EQ-5D from baseline to 2-year;

    Time frame: 24 months

  14. Medico economic impact

    Incremental Cost Effectiveness Ratio (ICER) defined as the cost for QALY gained in "treatment withdrawal group" versus "treatment continued group"

    Time frame: 24 months

07

Study locations

27 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Jul 2027, 102 months after the start.

Of 96 phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's planned 102 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2018
First posted
Aug 31, 2018
StartActual
Jan 24, 2019
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03653273
Responsible party
Sponsor
First posted
Aug 31, 2018
Start date
Jan 24, 2019
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Mar 30, 2026

Study contacts

Anne KERBRAT, Dr
principal investigator · CHU Rennes - National Headache Center
Clarisse SCHERER-GAGOU, Dr
principal investigator · University Hospital, Angers
Jean PELLETIER, Pr
principal investigator · AP-HM
Céline LOUAPRE, Dr
principal investigator · AP-HP La pitié Salpêtrière
Aurore JOURDAIN, Dr
principal investigator · CHU Brest
Pierre CLAVELOU, Pr
principal investigator · University Hospital, Clermont-Ferrand
Thibault MOREAU, Pr
principal investigator · CHU Dijon
Olivier CASEZ, Dr
principal investigator · University Hospital, Grenoble
Hélène ZEPHIR, Pr
principal investigator · CHU Lille
Sandra VUKUSIC, Pr
principal investigator · Hospices Civils de Lyon
Pierre LABAUGE, Pr
principal investigator · University Hospital, Montpellier
Guillaume MATHEY, Dr
principal investigator · Central Hospital, Nancy, France
David LAPLAUD, Pr
principal investigator · Nantes University Hospital
Christine LEBRUN-FRENAY, Pr
principal investigator · Centre Hospitalier Universitaire de Nice
Olivier HEINZLEF, Dr
principal investigator · CH Poissy
Jean-Philippe NEAU, Pr
principal investigator · CHU Poitiers
Marc COUSTANS, Dr
principal investigator · CH Quimper
Jérôme DE SEZE, Pr
principal investigator · CHU Strasbourg
Anne-Marie GUENNOC, Dr
principal investigator · CHU Tours
Caroline BENSA-KOSCHER, Dr
principal investigator · Fondation de Rothschild
Eric THOUVENOT, Pr
principal investigator · Centre Hospitalier Universitaire de Nīmes
Alain CREANGE, Pr
principal investigator · CH HENRI MONDOR
Arnaud KWIATKOWSKI, Dr
principal investigator · Hôpital Saint Vincent de Paul
Aurelie RUET, Pr
principal investigator · University Hospital, Bordeaux
Jérôme GRIMAUD, Dr
principal investigator · CH de Chartres
Maia TCHIKVILADZE, Dr
principal investigator · CH Foch
Philippe CASENAVE, Dr
principal investigator · CH de Libourne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion